Novartis could make a move if they thought M-Copax was coming on line, but I wouldn't think Novartis would have any desire if we're talking strictly from a cash flow position.
You could make a case if NVS strictly used stock to acquire Momenta but I can't see them using capital for the purchase.
Market Data 
Markets 
AI
